A Multi-centre, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Children in Canada (CATCO-Kids) [Funder: Montreal Children's Hospital Foundation]
- Funded by Other Funders (Canada)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
Other Funders (Canada)Principal Investigator
Papenburg, Jesse, Fontela PatriciaResearch Location
CanadaLead Research Institution
McGill UniversityResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Prophylactic use of treatments
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Randomized Controlled Trial
Broad Policy Alignment
Pending
Age Group
Children (1 year to 12 years)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Can anti-malaria drugs help children with COVID-19? CATCO is a Canada-wide study that is testing the efficacy of anti-malaria drug hydroxychloroquine to treat adults hospitalized with COVID-19. Now, pediatric infectious disease specialist Dr. Jesse Papenburg and pediatric critical care expert Dr. Patricia Fontela are performing a similar study on children to determine whether the drug can reduce the severity of the COVID-19 infection, and lead to faster recovery and shorter hospital stays. This study will be the first randomized trial in children with COVID-19, and has the potential to save young lives.